Abstract-The APOE e4 allele was originally reported to contribute to risk of Alzheimer's disease (AD) in women, yet male and female AD patient-derived data are routinely pooled. Histopathological hallmarks of AD include neurofibrillary tangles centered on hyperphosphorylated Tau and plaques composed of the b-amyloid (Ab) peptide that is derived by sequential secretase-mediated cleavage of the Amyloid Protein Precursor (APP). We chose to examine profiles of Ab (1-40), Ab (1-42), and N-truncated (i.e., p3-related) fragments in the plaqueassociated fraction of autopsied cortical and corresponding hippocampal samples from donors with a diagnosis of early-onset (EOAD) and late-onset (LOAD) AD. Levels of Ab (1-40), Ab (1-42), and the p3 fragment-enriched pool were increased in EOAD and LOAD samples, and correlated well within -but not between-regions. Counterintuitively, these increases were similar regardless of the AD donor's APOE e4 status. Focusing on the donor's sex and APOE e4 status as nominal variables (i.e., omitting diagnosis from the stratification) revealed that increases in Ab peptides were specific to female carriers of the e4 allele and correlated with the proportional expression of BACE1/b-secretase and ADAM10/a-secretase in the cortex and with nicastrin (c-secretase) expression in the hippocampus. These data preliminarily support the possibility that AD follows distinct amyloidogenic processes in males and females, and that the APOE e4 allele exerts a major influence on the disease process, particularly in women. This knowledge could significantly impact the (re)interpretation of unsuccessful outcomes of clinical interventions targeting either Ab peptides directly or the secretases implicated in APP processing. Ó 2018 Published by Elsevier Ltd on behalf of IBRO.
INTRODUCTION

14
Alzheimer disease (AD) is identified by overt behavioral 15 and cognitive phenotypes that are thought to reflect 16 pathology centered on the hippocampal formation and 17 associated structures (West, 1993) . Unfortunately, toms invariably present at an advanced stage of disease 19 progression that precludes effective intervention (Prins 20 et al., 2010) . Risk factors for AD-related dementia, includ- Amyloid Protein Precursor) (Glenner and Wong, 1984) https://doi. 1994 Canadian Study of Health and Aging (CHSA) report 85 estimates a female/male ratio of 2.7 in AD (McDowell 86 et al., 1994) , whereas a more recent CHSA report 87 (Lindsay et al., 2002) and the Framingham study 88 (Bachman et al., 1993) (Poirier et al., 1993; Tanzi, 2012 men (Poirier et al., 1993; Payami et al., 1996; Farrer 106 et al., 1997; Bretsky et al., 1999) Parkinson's disease patients and neurologically normal 117 controls (Federoff et al., 2012) . the 28-to 39-mers) (Seubert et al., 1992; Suzuki et al., 125 1994; Wang et al., 1996) as well as N-truncated Ab pep-126 tides, including the p3 fragment, i.e., 127 (Kummer and Heneka, 2014 The use of autopsied tissues in this study is covered by 156 the University of Saskatchewan's Research Ethics Representative gels from resolved 6E10-immunoprecipitates immunoblotted for 6E10, and 4G8-immunoprecipitates immunoblotted for 4G8 in cortical (upper panels) and corresponding hippocampal (lower panels) samples. The experiment included control samples as well as samples from male and female donors diagnosed with Early-Onset AD (EOAD) or Late-Onset AD (LOAD). Respective ages and APOE genotypes are indicated, with carriers (i.e., 2/4, 3/4) and non-carriers (i.e., 2/3, 3/3) of the e4 allele being represented. Bands corresponding to Ab (1-40), Ab (1-42), and to the N-truncated / p3 fragment-enriched pool are identified. , and EO (n = 9) and LO (n = 10) AD. Hippocampal male samples represent control (CTL: n = 6), and Early-Onset (EO: n = 7) and Late-Onset (LO: n = 8) AD, while hippocampal female samples represent CTL (n = 12), and EO (n = 8) and LO (n = 10) AD. (Mendez et al., 2015) . 391 Wiltfang's Urea/SDS-PAGE system (Wiltfang et al., 392 1997) easily discriminated between synthetic Ab peptides 393 of varying lengths, i.e., Ab (1-38), Ab (1-40), Ab (1-42) 394 and Ab (1-43), in contrast with standard 15% SDS-395 PAGE, which did not (Fig. 1) . The Urea/SDS-PAGE sys- . Ab peptide levels stratified by APOE e4 status of the donor. The levels of Ab (1-40) and Ab (1-42) from (left) cortical and (right) hippocampal samples were stratified solely according to whether the donor was a non-carrier (-e4: cortex: n = 29; hippocampus: n = 21) or a carrier (+e4: cortex: n = 31; hippocampus: n = 30) of the APOE e4 allele. The ratios of Ab (1-42)/Ab (1-40) are included for both regions. [P = 0.7457] (Fig. 11) . (Fig. 13) hippocampal samples (Fig. 14) . Bretsky et al., 1999) . Furthermore, the effect of the e4 682 allele is more evident in the cortical samples, which also 683 supports the temporal pattern of amyloid burden that 684 has been associated with AD progression, i.e., cortex 685 first, followed by hippocampus (Oddo et al., 2003) . ited -or generated-in this region of the female brain; in to male carriers or non-carriers in general) (Ungar et al., 883 2014).
884
In support of gender-risk associated with the e4 885 genotype, female carriers (but not males) are more . BACE1 and ADAM10 expression levels stratified by APOE e4 status and sex of the donor. The levels of (top panels) BACE1 (b-secretase) and (middle panels) ADAM10 (a-secretase) were stratified by sex and APOE e4 status. (bottom panels) These data were used to determine the ratio of BACE1 to ADAM10 in corresponding cortical (left) and (right) hippocampal samples. Samples sizes are as indicated in Fig. 7 , except for hippocampal female + e4, where a data point was excluded as an outlier (n = 15). and e2 alleles (Huang et al., 2017 (Nistor et al., 2007) , from primarily N-truncated/p3-974 related species to Ab-related products of APP (Lalowski 975 et al., 1996) . Given that glia tend to provide more of an 976 influence in the DS brain (Chen et al., 2014) 
